NOVO NORDISK A S (NVO) Form 6-K — Sep 15, 2026
Novo Nordisk filed a Form 6-K with its weekly share repurchase update, confirming continued buybacks under the DKK 15 billion programme it launched on 4 February 2026 for a 12-month period. In the trading week of 7-11 September 2026, the company purchased 210,000 B shares each day at average prices between DKK 278.62 and DKK 297.98, lifting accumulated purchases under the 6 May tranche to 18,325,000 B shares for a total of DKK 5,526,186,488. Since 4 February 2026, Novo Nordisk has repurchased 33,084,179 B shares at an average price of DKK 281.89, equal to DKK 9,326,186,478 - roughly DKK 5.7 billion of capacity left on the DKK 15 billion authorization.
Key figures
- Tranche window
- 6 May 2026 to 1 February 2027
- Treasury shares
- 47124876
- Program size dkk
- DKK 15 billion over 12 months beginning 4 February 2026
- Daily shares repurchased
- 210000
- Total shares outstanding
- 4465000000
- Daily avg price range dkk
- DKK 278.62 - DKK 297.98
- Accumulated tranche shares
- 18325000
- Accumulated tranche value dkk
- 5526186488
- Treasury pct of share capital
- 1.1%
- Repurchased since feb2026 shares
- 33084179
- Repurchased since feb2026 value dkk
- 9326186478
- Repurchased since feb2026 avg price dkk
- 281.89
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.